PBPK Modeling of PAXLOVID<sup>TM</sup>: Incorporating Rotamer Conversion Kinetics to Advanced Dissolution and Absorption Model.

Jaini, Rohit; Lin, Jian; Di, Li; Sagawa, Kazuko

PBPK Modeling of PAXLOVID^TM: Incorporating Rotamer Conversion Kinetics to Advanced Dissolution and Absorption Model.

Jaini, Rohit; Lin, Jian; Di, Li; Sagawa, Kazuko.

Afiliação

Jaini R; Drug Product Design, Pharmaceutical Sciences Small Molecule, Pfizer Inc., Cambridge, MA 02139, United States.
Lin J; Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, CT 06340, United States.
Di L; Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, CT 06340, United States.
Sagawa K; Drug Product Design, Pharmaceutical Sciences Small Molecule, Pfizer Inc., Groton, CT 06340, United States. Electronic address: kazuko.sagawa@Pfizer.com.

J Pharm Sci ; 113(1): 64-71, 2024 01.

Article em En | MEDLINE | ID: mdl-37805075

Assuntos

RNA Viral; Ritonavir; Humanos; Criança; Solubilidade; Antivirais

Palavras-chave

Absorption; Human pharmacokinetics; Nirmatrelvir; PBPK modeling; Paxlovid; Ritonavir; Rotamer conversion

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Viral / Ritonavir Tipo de estudo: Guideline / Prognostic_studies Limite: Child / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google